1. Home
  2. PKG vs ALNY Comparison

PKG vs ALNY Comparison

Compare PKG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Packaging Corporation of America

PKG

Packaging Corporation of America

N/A

Current Price

$250.88

Market Cap

22.9B

ML Signal

N/A

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

N/A

Current Price

$165.14

Market Cap

21.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PKG
ALNY
Founded
1867
2002
Country
United States
United States
Employees
13600
115
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9B
21.6B
IPO Year
1999
2004

Fundamental Metrics

Financial Performance
Metric
PKG
ALNY
Price
$250.88
$165.14
Analyst Decision
Buy
Buy
Analyst Count
10
30
Target Price
$269.22
★ $299.96
AVG Volume (30 Days)
665.7K
★ 3.1M
Earning Date
10-21-2026
10-29-2026
Dividend Yield
★ 2.39%
N/A
EPS Growth
N/A
★ 206.88
EPS
6.98
★ 18.42
Revenue
★ $8,989,300,000.00
$1,037,418,000.00
Revenue This Year
$12.21
$46.57
Revenue Next Year
$8.81
$19.91
P/E Ratio
$35.95
★ $8.93
Revenue Growth
7.23
★ 22.88
52 Week Low
$191.50
$149.18
52 Week High
$262.59
$479.79

Technical Indicators

Market Signals
Indicator
PKG
ALNY
Relative Strength Index (RSI) 54.19 34.57
Support Level $221.41 N/A
Resistance Level $259.24 $237.47
Average True Range (ATR) 6.60 10.41
MACD -0.65 -0.83
Stochastic Oscillator 41.72 19.58

Price Performance

Historical Comparison
PKG
ALNY

About PKG Packaging Corporation of America

Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: